Expression of the insulin-like growth factor-1 receptor and its anti- apoptotic effect in malignant melanoma: A potential therapeutic target

Melanoma Research

Volumn 8, Issue 5, 1998, Pages 389-397

  Kanter Lewensohn, L ^a   Dricu, A ^a   Wang, M ^a   Wejde, J ^a   Kiessling, R ^a   Larsson, O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Immunohistochemistry; Insulin like growth factor 1 receptor; Malignant melanoma; Metastasis; N linked glycosylation; Western blotting

Indexed keywords

SOMATOMEDIN C; SOMATOMEDIN RECEPTOR;

APOPTOSIS; ARTICLE; CELL VIABILITY; GROWTH DISORDER; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; PRIORITY JOURNAL;

EID: 0031772310     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199810000-00002     Document Type: Article

References (20)

1. Dricu A, Carlberg M, Wang M, Larsson O. Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Cancer Res 1997; 57: 543-548.
2. Carlberg M, Dricu A, Blegen H, Wang M, Hjertman M, Zickert P, Höög A, Larsson O. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. J Biol Chem 1996; 271: 17453-17462.
3. Salazar-Onfray F, Nakazawa T, Chhajlani V, Petersson M, Kârre K, Masucci G, Celis E, Sette A, Southwood S, Appella E, Kiessling R. Synthetic peptides derived from the melanocyte stimulating hormone receptor MC1R can stimulate HLA-A2 restricted CTL that recognize naturally processed peptides on human melanoma cells. Cancer Res 1997; 57(19): 4348-4355.
4. Gammeltoft S. In: Peptide hormone receptors Siddle K. Hutton JC, eds. Peptide Hormone Action. A Practical Approach. Oxford: Oxford University Press, 1990: 1-41.
5. Laemmli UK. Cleavage of structural proteins during the assembly of the head of backeriophage T4. Nature 1970; 227: 680-685.
6. Larsson O, Carlberg M, Zetterberg A. Selective killing induced by an inhibitor of N-linked glycosylation. J Cell. Sci 1993; 106: 299-307.
7. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
8. Dricu A, Wang M, Hjertman M, Malec M, Blegen H, Wejde J, Carlberg M, Larsson O, Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Kas phenylation and expression of c-myc. Glycobiology 1997; 7: 625-633.
9. Ullrich A, Gray A, Tam AW, Yang-Feneg T, Tsubokawa M, Collins C, Henzet W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J, Fujita-Yamaguchi Y. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 5: 2503-2512.
10. Baserga R. The insulin-like growth factor 1 receptor: a key to tumor growth? Cancer Res 1995; 55: 249-252.
11. Kalebic T, Tsokos M, Helman L. In vivo treatment with antibody against the IGF-I receptor suppresses growth of human rhabdomyosarcoma and down regulates p34/cdc2. Cancer Res 1994; 54: 5531-5534.
12. Resnicoff M, Sell C, Rubini M, Coppola O, Ambrose D, Baserga R, Rubin R. Rat glioblastoma cells expressing an antisense RNA to insulin-like growth factor-1 (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54: 2218-2222.
13. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994; 54: 4848-4850.
14. Shapiro DN, Jones BG, Shapiro LH, Dias P, Houghton PJ. Antisense-mediated reduction in insulin-like growth factor 1 receptor expression suppresses the malignant phenotype of human alveolar rhabdomyosarcoma. J Clin Invest 1994; 94: 1235-1242.
15. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor mutant. Proc Natl Acad Sci USA 1994; 91: 2181-2185.
16. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman H, Kajstura J, Rubin R, Zoltick P, Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995; 55: 2463-2469.
17. Harrington EA, Bennet MR, Fanidi A, Evan GI. C-myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 1994; 13: 3286-3295.
18. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 1995; 55: 303-306.
19. Evan G, Wyllie AH, Gilberts CS, Littlewood TD, Land H, Brooks M, Peen LZ, Hancock DC. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
20. Rubini M, Hongo A, D'Ambrosio C, Baserga R. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res 1997; 230(2): 284-292.